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Abstract
Background: This study is a pre-planned country-specific subanalysis of results in Germany from a multinational
multicenter registry to prospectively assess real-world experience with caspofungin administered for treatment of
proven or probable invasive aspergillosis (IA).
Methods: Data from patients treated with caspofungin for a single episode of IA were collected. Effectiveness was
determined by the local investigator as favorable (complete or partial response) or unfavorable (stable disease,
failure or death) at the end of caspofungin therapy. Descriptive statistics with binomial exact confidence intervals
were employed.
Results: Forty-two consecutive patients were identified in three German centers. Three patients (7%) had proven IA
and 39/42 (93%) had probable IA (modified European Organization for Research and Treatment of Cancer/Mycosis
Study Group (EORTC/MSG) criteria). Forty-one patients had pulmonary IA and one had tracheal IA. Caspofungin
monotherapy was received by 36/42 patients (86%); of these, 26/36 (72%) received salvage therapy. A favorable
response was observed in 29/42 patients (69%; 95% CI 53 to 82%); of these, 21/29 (72%) had a complete and 8/29
(28%) a partial response. Favorable response rate was 69% in patients with monotherapy (95% CI 52% to 84%; 25/
36 patients), and 67% in patients receiving combination therapy (95% CI 22% to 96%; 4/6 patients). Favorable
response rate in patients with first line therapy was 64% (95% CI 31% to 89%; 7/11 patients), and 73% in patients
with second line therapy (95% CI 54% to 88%; 20/30 patients). No adverse events were reported. In total, 35/42
patients (83%; 95% CI 69 to 93%) survived seven days after completion of caspofungin therapy.
Conclusions: These real-life findings in Germany are consistent with the international findings from this registry
and with findings from randomized studies.
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Introduction
Invasive aspergillosis poses a major threat to patients with
hematologic diseases and can greatly jeopardize the suc-
cess of treatment of the underlying condition [1]. Among
patients with hematologic and oncologic conditions,
patients who have undergone stem cell transplantation
form a particularly high risk group for invasive aspergillo-
sis. Other risk factors are major surgical procedures, HIV/
AIDS, cancer, immunosuppressive therapy and advanced
age [2]. Invasive aspergillosis is associated with mortality
rates of 30% to 90% [3], and the one-year survival rate of
patients with fungal infections following stem cell trans-
plantation has been reported to be as low as 20% in some
cases. Donhuijsen et al. found invasive mycosis to be pre-
sent in 340 of 1,591 autopsied patients with hematologic
neoplasias, the proportion of aspergillosis among these
cases rising from 28% in the period 1976 to 1980 to 89%
in the period 2001 to 2005 [4].
Current guidelines recommend treatment with azoles,
polyenes and echinocandins [1,5]. Caspofungin is the
only echinocandin presently licensed in Europe for the
treatment of invasive aspergillosis, being approved for the
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patients who are refractory to or intolerant of, for exam-
ple, amphotericin B and as empirical therapy for pre-
sumed fungal infections (such as Candida or Aspergillus)
in febrile neutropenic adult or pediatric patients [6].
The purpose of the registry was to collect data on the
use of caspofungin in everyday clinical practice in patients
with invasive aspergillosis. As data from Germany on this
disease have not previously been available, we present here
the results of a pre-planned national subanalysis.
Methods
Patients treated in hospitals in Australia, Belgium, Brazil,
Germany, Greece, Jordan, Korea, Russia, Singapore, Slove-
nia and Taiwan were consecutively included in the inter-
national registry in the period from April 2006 to
September 2007 [7].
The study was submitted to the responsible ethics com-
mittees in accordance with local regulations. Inclusion cri-
teria were informed consent by the patient, age at least
16 years, a diagnosis of proven or probable invasive asper-
gillosis, mono- or combination therapy with caspofungin,
and non-participation in any clinical trial on antimycotic
therapy sponsored by MSD or Merck & Co. The infection
was classified as invasive aspergillosis by the treating phy-
sician on the basis of the individual clinical assessment
and local diagnostic and treatment standards. As an aid to
classification of the Aspergillus infection as probable or
proven, the treating physicians were provided with the cri-
teria of the European Organisation for Research and
Treatment of Cancer/Mycoses Study Group of the year
2002 [8]. There were no exclusion criteria.
No study medication was supplied in connection with
this registry. Dosage in the individual patient was deter-
mined by the physician on the basis of the drug prescrib-
ing information [6] and local treatment standards. One
treatment cycle with caspofungin was documented for
each patient. Patients included in the registry were
observed from the start of their period of hospitalization
until their discharge or death. The decision to treat was
taken by the treating physician alone on the basis of the
patient’s clinical situation.
The data collected consisted of patient data (for exam-
ple, gender, weight and age), previous illnesses, risk factors
and information on caspofungin therapy, such as date
commenced, duration, dose, response and previous treat-
ment. Also collected were data on the patient’s general
condition, neutropenic status, liver function and organ
involvement; microbiologic findings; drug interactions;
safety; and concomitant antimycotic medication. At the
end of treatment data on survival, clinical condition,
results of imaging investigations, microbial resistance and
efficacy were collected.
The objective was to assess real-world effectiveness on
the basis of an assessment of individual response to treat-
ment undertaken by the treating physician at the end of
caspofungin administration in accordance with standar-
dized criteria [9], whereby only complete or partial remis-
sion was deemed to constitute a response. A complete
response to treatment with caspofungin was deemed to
be present if in the opinion of the treating physician all
clinical signs and symptoms of IA and all radiologic and
bronchoscopic abnormalities had resolved completely by
the end of treatment. A partial response required a clini-
cally significant improvement in all clinical signs and
symptoms consistent with IA and a pronounced
improvement in radiologic (at least 50%) and broncho-
scopic abnormalities, and was considered to be present -
independent of the extent of clinical or radiologic
improvement - even in the presence of persistent radiolo-
gic changes. Non-response to treatment was defined as
stable disease, treatment failure or death.
For the assessment of safety, the physicians were
required to report serious and non-serious clinical and
laboratory adverse events that were possibly, probably or
definitely related to the caspofungin therapy. Serious
adverse events were defined as adverse events that were
life-threatening; that resulted in death or hospitalization or
prolongation of a period of hospitalization; or that led to
inability to work; and included congenital anomalies, can-
cers and all complications, which, from a medical point of
view, are to be regarded as serious. An independent expert
panel reviewed the analysis of the entire international data
for accuracy and completeness [7].
The analysis was descriptive. Binomial exact 95% confi-
dence intervals (CIs) were calculated with the aid of SAS
PROC FREQ.
Results
Data were collected from 42 patients from three centers in
Germany (out of a worldwide total of 103 patients); 43%
of the patients (18/42) were female and 57% (24/42) male.
Median patient age at onset of disease was 57 years (range
17 to 75 years). Median weight was 74 kg (range 44 to 98
kg). Underlying dísease was active malignancy in 39/42
patients (93%; Acute myeloic leukemia - 28, lymphoma -
4, myeloma - 3, acute lymphatic leukemia - 2, breast can-
cer - 1, other - 1), and organ transplantation in 3/42
patients (7%). The patients suffered from a median of four
comorbidities, for example, 16/42 (38%) had pulmonary
disease; and 10/42 (24%) had arterial hypertension, or
heart disease, respectively. History-taking revealed a med-
ian of five risk factors, for example, before receiving caspo-
fungin 41/42 patients (98%) had received broad-spectrum
antibiotics and 39/42 patients (93%) immunosuppressants.
For further information, see Table 1.
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Page 2 of 7The standard caspofungin regimen, that is, 70 mg on
Day 1 and 50 mg from Day 2, was given in 38/42 patients
(90%). One patient received a lower dosage (50 mg on Day
1 and 30 mg from Day 2) and three patients a higher
dosage (70 mg on Day 1 and 70 mg from Day 2). Informa-
tion on the use of caspofungin mono- and combination
therapy, and pretreatment with antimycotic agents, is
g i v e ni nT a b l e2 .T h em e d i a nd u r a t i o no fc a s p o f u n g i n
treatment was 11 days (mean 18.4, range 5 to 152, n = 42)
for all patients and 11 days (mean 13.7, range 5 to 38; n =
36) for the monotherapy group.
The treating physicians considered that all the patients
were suffering from invasive aspergillosis, this diagnosis
being regarded as proven in 3/42 patients (7%; in 2
patients Aspergillus fumigatus, in 1 patient not further
specified) and probable in 39/42 patients (93%; diagnosis
in these case was based on the investigator’s judgment).
Pulmonary involvement was present in 41/42 patients
(98%) and tracheal involvement in 1patient. The absolute
neutrophil count at the start of treatment was < 500 in
28/42 patients (67%). Prior antimycotic therapy had been
Table 1 Demographic data and patient characteristics
Variable Caspofungin monotherapy
(N = 36)
Caspofungin combination therapy
(N = 6)
Total
(N = 42)
Gender, n (%)
Male 22 (61%) 2 (33%) 24 (57%)
Female 14 (39%) 4 (67%) 18 (43%)
Age (years; median (range)) 59 (20 to 75) 42 (17 to 57) 57 (17 to 75)
Affected organ, n
Lung 35 6 41
Trachea 1 0 1
Neutropenic status at start of caspofungin therapy
Neutrophilic granulocytes < 500/μL 27 (75%) 1 (17%) 28 (67%)
Neutrophilic granulocytes ≥ 500/μL 9 (25%) 5 (83%) 14 (33%)
No. of risk factors per patient
(median (range))
5 (3 to 9) 7 (3 to 7) 5 (3 to 9)
Risk factors, n (%)*’
Active cancer 35 (97%) 4 (67%) 39 (93%)
Immunosuppressive therapy 34 (94%) 5 (83%) 39 (93%)
Neutropenia at hospitalization 26 (72%) 1 (17%) 27 (64%)
Allogeneic HSCT 5 (14%) 3 (50%) 8 (19%)
Prior colonization with fungi 5 (14%) 1 (17%) 6 (14%)
Acute renal disease 4 (11%) 1 (17%) 5 (12%)
Diabetes mellitus 4 (11%) 1 (17%) 5 (12%)
Autologous HSCT 4 (11%) 0 4 (10%)
AIDS/HIV disease 3 (8%) 0 3 (7%)
*Odered by frequency. ‘Multiple answers possible. HSCT hematopoetic stem cell transplantation
Table 2 Patients treated with caspofungin
Type of use Monotherapy
(N = 36)
Combination therapy
(N = 6)
Total
(N = 42)
Caspofungin first-line therapy* 10 (28%) 1 (17%) 11 (26%)
Caspofungin second-line therapy** 26 (72%) 5 (83%) 31 (74%)
Thereof reason for switching to caspofungin
Clinically refractory to first-line therapy 21 (58%) 5 (83%) 26 (62%)
Toxicity with first-line therapy 2 (6%) 0 2 (5%)
Other** 3 (8%) 0 3 (7%)
*The reason for using caspofungin as the first line therapy was “probable aspergillosis” in 10 patients and “proven aspergillosis” in 1 patient.
**In 25 patients, this consisted of azoles (9 posaconazole, 7 voriconazole, 6 fluconazole (of these, 5 for prophylactic use and 1 for unknown reasons),3
itraconazole), in 5 patients polyenes (2 amphotericin colloidal dispersion, 3 liposomal amphotericin B), and in 1 patient other antimycotics. Prior antimycotic
therapy had been given for a mean duration of 13.2 days.
**Breakthrough infection during azole prophylaxis
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(SD 7.9) days. For further information, see Table 2.
The treating physicians considered that 29/42 patients
(69%; 95% CI 53 to 82%) responded to treatment. Of
these, 21/29 patients (72%) showed a complete response
and 8/29 patients (28%) a partial response. In 10 patients,
the disease remained stable. One patient, who had
received prior treatment with liposomal amphotericin B,
was classified by the treating physician as showing treat-
ment failure after eight days of caspofungin therapy. A
patient with AML, who had received prior prophylactic
therapy with fluconazole for four days followed by six days
of treatment with caspofungin and then three days of
treatment with voriconazole, died of cerebral aspergillosis.
Data on real-world effectiveness are absent for one patient
who received combination therapy. Further details are
given in Table 3. The survival rate seven days after the end
of caspofungin therapy was 83% overall (35/42 patients;
95% CI 69 to 93%) and 89% (25/28 patients; 95% CI 75 to
97%) in patients with neutropenia at the start of caspofun-
gin therapy. A total of 34/42 patients (81%) were alive at
hospital discharge, of whom 28 patients were discharged
home, and 6 were discharged to another institution. A
total of 7/42 patients (17%) had died in hospital, and there
was one patient with unknown status at hospital discharge
(2%).
In no patient was the caspofungin therapy stopped
because of a drug interaction between caspofungin and
another antifungal agent. The treating physicians consid-
ered that there were no serious or non-serious clinical or
laboratory adverse events possibly, probably or definitely
related to the caspofungin therapy. A total of 28 patients
were discharged home after the end of their period of
hospitalization and six patients were transferred to
another institution. Seven patients died during the obser-
vation period; in none of these cases did the treating phy-
sician consider there to be a causal relationship with the
antifungal therapy.
Discussion
In a randomized double-blind study by Walsh et al. [10]
on the use of caspofungin vs. liposomal amphotericin B
as empirical therapy in neutropenic patients with sus-
pected invasive fungal disease, 24 cases of pre-existing
invasive aspergillosis that were unrecognized at the start
of treatment were identified, with 12 such cases in each
treatment arm. The response rate was 42% in the caspo-
fungin arm and 8% in the liposomal amphotericin B arm.
Table 3 Real-world effectiveness of treatment as assessed by the treating physician (n = 41/42*)
Variable Response, % (n/N) [95% CI]
Overall 70.7 (29/41) [54.5 to 83.9]
Probable aspergillosis 71.8 (28/39) [55.1 to 85.0]
Proven aspergillosis 50.0 (1/2) [37.4 to 74.5]
Combination therapy** 80.0 (4/5) [28.4 to 99.5]
Monotherapy 69.4 (25/36) [51.9 to 83.7]
First-line therapy*** 63.6 (7/11) [30.8 to 89.1]
Second-line therapy 73.3 (20/30) [54.1 to 87.7]
Neutropenic status at start of caspofungin therapy
Neutrophilic granulocytes < 500/uL 71.4 (20/28) [51.3 to 86.8]
Neutrophilic granulocytes ≥ 500/uL 69.2 (9/13) [38.6 to 90.9]
Risk factors****
Allogeneic HSCT 87.5 (7/8) [47.3 to 99.7]
Acute renal disease 80.0 (4/5) [28.4 to 99.5]
Neutropenia at hospitalization 70.4 (19/27) [49.8 to 86.2]
Active cancer 69.2 (27/39) [52.4 to 83.0]
Immunosuppressive therapy 68.4 (26/38) [51.3 to 82.5]
Prior colonization with fungi 66.7 (4/6) [22.3 to 95.7]
Autologous HSCT 50.0 (2/4) [6.8 to 93.2]
* No data were available for one lung transplant patient with proven aspergillosis (A. fumigatus), who had received triple combination therapy (amphotericin B,
caspofungin, voriconazole). If this patient is regarded as a failure, the response rate for all 42 patients is: favorable response, 29/42 patients (69%; 95% CI 53 to
82%).
** Combination of caspofungin with amphotericin B desoxycholate (two patients), with fluconazole (one patient), with posaconazole (one patient), with
amphotericin B desoxycholate plus voriconazole (one patient). Note, if the patient described in * is included in the effectiveness population and (post hoc)
counted as a failure, the response rate for patients with combination therapy is 66.7% (4/6) and the 95% confidence interval is 22.2% to 95.7%.
*** All patients receiving caspofungin first line were on monotherapy.
**** Multiple answers possible.
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domized studies are in the range 33 to 56% [9,11-13]. In
our group of patients the use of caspofungin under real-
world conditions in Germany likewise led to high
response and survival rates; whereas, the response rate in
patients with proven or probable IA in the international
study, of which this forms a part, was 56% (57/101; 95%
CI 47 to 66%), a figure that is within the range of pre-
viously published results [7]. The response rate in the
subanalysis for Germany was higher, namely 69% (29/41;
95% CI 54 to 84%). Technical, social and psychological
standards and conditions in health care may vary across
countries and sites and impact on diagnostic accuracy.
On the other hand, patients in Germany were treated
much earlier than the patients in other countries, as evi-
denced by the fact that the proportion of patients with
proven aspergillosis was only 7% in the German popula-
tion compared to 30% internationally. The Infectious
Diseases Working Party (AGIHO) of the German Society
for Hematology and Oncology (DGHO) recently issued a
BIII recommendation advising early initiation of treat-
ment at the first sign of IA, as this improves the probabil-
ity of survival [1]. The licensed first-line treatments for
invasive aspergillosis likewise show higher response rates
when used earlier. For example, in an unblinded study on
primary therapy of invasive aspergillosis with voricona-
zole, 30/67 patients (45%) with definite invasive aspergil-
losis responded to treatment compared to 46/66 patients
(60%) with probable aspergillosis (defined as the presence
of a halo or cavitation with an air-crescent sign in a
patient with neutropenia or allogeneic SCT) [14]. In a
double-blind study on primary therapy of invasive asper-
gillosis, Cornely et al. investigated the use of liposomal
amphotericin B at different dose levels (3 mg vs. 10 mg/
kg bodyweight) [15]. The overall response rate in the 107
patients who received the licensed dose of 3 mg/kg body-
weight was 50%. Interestingly, the diagnosis was consid-
ered to be probable (defined as the presence of a halo or
cavitation with an air-crescent sign in a patient with neu-
tropenia or allogeneic SCT) in 99/107 patients and pro-
ven in only 8/107 patients. In our study, 11/42 patients in
Germany (26%) received caspofungin as primary therapy
(in one case as part of combination therapy) compared to
20% of patients internationally. These patients who
received primary therapy with caspofungin showed a
response rate of 64% compared to 60% internationally.
Unlike the patients from other countries, none of the
patients from Germany had Aspergillus fungemia. Most
(74%) of our patients were given caspofungin as salvage
therapy. Caspofungin is licensed for use as second-line
therapy of invasive aspergillosis and is given an AII
recommendation for this purpose in the current AGIHO
guidelines. In addition, the guidelines of the European
Conference on Infections in Leukemia (ECIL) give
caspofungin a CII recommendation for primary therapy
of invasive aspergillosis, whereas it gives voriconazole a
recommendation of AI or CIII (when initiated orally) and
liposomal forms of amphotericin B a BI or BII recom-
mendation, respectively [5]. One possible reason why cas-
pofungin was used in the patients considered here may
be the high potential that azoles have for interaction with
modern oncologic therapies - in particular with vinca-
alkaloids - because of cytochrome P450 metabolism [1].
Also notable in this regard is the hepatotoxicity and
nephrotoxicity of the polyenes [16,17]. Interestingly, in
the patients in our series caspofungin was used primarily
because of non-response to, and/or toxicity of, previous
treatment. The treating physicians did not report any
adverse events possibly, probably or definitely related to
caspofungin therapy.
The patients in this series were severely ill patients in
whom it was, therefore, especially important to ensure
successful treatment of the underlying condition: 79%
were suffering from a malignant or hematologic disease,
93% were receiving immunosuppressive therapy, 98% had
recently received a broad-spectrum antibiotic, 64% were
neutropenic and 45% had a central venous catheter in
place. This circumstance may also explain why a propor-
tion of patients (14%) were given combination therapy
despite the paucity of evidence to support such treatment.
Whereas the average duration of caspofungin treatment in
this real-life setting was at the lower end of what has been
reported in earlier studies, the total range reported here is
completely in line with what previously has been reported
[9,11-13].
Synergistic effects among echinocandins and amphoteri-
cin B and azoles have been demonstrated in vitro [18].
Recently Caillot et al. [19] reported the first evidence from
a randomized study that use of liposomal amphotericin B
(3 mg/kg) in combination with caspofungin in invasive
aspergillosis achieves a higher response rate at the end of
treatment than does high-dose liposomal amphotericin B
alone, whereby the combination showed good tolerance
and achieved a 12-week survival of 100%. Further studies
are required to confirm the value of combination therapy
in invasive aspergillosis.
The limitations of the present study include its one-
armed observational design. Also, the assessment of real-
world effectiveness was based exclusively on evaluation
by the treating physician and local diagnostic and treat-
ment standards, and information regarding the rationale
for the use of the pre-caspofungin first line treatment is
limited. The classification of invasive aspergillosis was
based on the 2002 EORTC/MSG criteria [8], and nearly
all the Aspergillus infections (93%) had been classified by
the treating physician as probable and were not reviewed
by a panel. Moreover, patients who show signs that are
highly suggestive of Aspergillus infection could also be
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small number of patients resulted in generally broad con-
fidence intervals. No deaths associated with the caspo-
fungin therapy were reported; however, the causes of the
deaths that occurred were not determined. The follow-up
period after the end of caspofungin therapy was relatively
short.
Conclusions
Based on assessment by the treating physicians, patients in
Germany with proven or probable invasive aspergillosis
showed an overall response rate of 69% to caspofungin
therapy. The side-effect and interaction profiles were
favorable. These results were obtained in a patient popula-
tion composed largely of high-risk patients with active
cancer or neutropenia. The results of this pre-planned
Germany-specific analysis are consistent with the results
obtained in the overall cohort and with the results of ran-
domized clinical studies on the use of caspofungin in
patients with invasive aspergillosis.
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